If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Recognizing early signs such as confusion, vision changes, or weakness is critical for timely intervention. Building on decades of research into drug safety and neurological complications, this page outlines the key symptoms to watch and who may require heightened surveillance.
Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus. PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, emphasizing that the drug increases the risk of PML and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML, withholding dosing immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Clinical trial data document PML occurrence in Tysabri recipients. In the multiple sclerosis population, two cases of PML were observed among 1869 patients treated for a median of 120 weeks; both patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In the Crohn's disease population, one case occurred after eight doses among 1043 patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases highlight the potential for PML even with relatively short exposure, though longer treatment duration increases risk. The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits adhesion and migration of leukocytes across the blood-brain barrier. This reduces immune surveillance in the central nervous system, allowing reactivation of latent JC virus, which then causes lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The presence of anti-JCV antibodies indicates prior JC virus exposure and is a key risk factor, as patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Clinical presentation of PML is variable but typically includes subacute onset of neurological deficits such as hemiparesis, visual field defects, cognitive impairment, ataxia, and speech disturbances. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid by polymerase chain reaction, or brain biopsy. The FDA label advises that healthcare professionals should monitor patients on Tysabri for any new sign or symptom that may be suggestive of PML, and that Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Risk anchors for affected patients include the adequacy of warnings. The boxed warning and the TOUCH Prescribing Program are designed to ensure that patients and prescribers are informed of the PML risk and that monitoring occurs. However, causation-related considerations for affected patients involve the interplay of risk factors. For example, a patient with anti-JCV antibodies who has been on Tysabri for more than two years and has prior immunosuppressant use is at higher risk. The timeline between exposure and documented harm can vary. In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in one Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing data indicate that PML can occur at any time during treatment, but risk increases with longer duration. The FDA label also notes that Tysabri should not be used in combination with immunosuppressants or inhibitors of TNF-alpha in Crohn's disease, as this may further increase PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For multiple sclerosis, Tysabri is indicated as monotherapy, and the label advises that physicians should consider whether the expected benefit is sufficient to offset the PML risk when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) increases the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus. The FDA has issued a boxed warning and requires a restricted distribution program (TOUCH) due to this risk. The mechanism involves reduced immune surveillance in the central nervous system, allowing JC virus reactivation. Risk factors include anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
PML symptoms include subacute onset of neurological deficits such as hemiparesis, visual field defects, cognitive impairment, ataxia, and speech disturbances. Diagnosis is made by brain MRI showing white matter lesions and detection of JC virus DNA in cerebrospinal fluid or brain biopsy. Healthcare professionals should monitor for any new symptoms and withhold Tysabri immediately if PML is suspected (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.